The Genome-Based Drug Market is expected to register a CAGR of 9.5% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The Genome-Based Drug Market report covers analysis by Application (Oncology, Cardiovascular, Metabolic, Rare Diseases); End-User (Research Centers, Academic and Government Institutes, Pharmaceutical and Biotechnology Companies, Others), and Geography (North America, Europe, Asia Pacific, and South and Central America). The global analysis is further broken-down at regional level and major countries. The report Offers the Value in US$ for the above analysis and segments.
Purpose of the ReportThe report Genome-Based Drug Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Genome-Based Drug Market Segmentation
Application- Oncology
- Cardiovascular
- Metabolic
- Rare Diseases
- Research Centers
- Academic and Government Institutes
- Pharmaceutical and Biotechnology Companies
Strategic Insights
Genome-Based Drug Market Growth Drivers- Advancements in Genomic Technologies: Recent breakthroughs in sequencing technologies, such as next-generation sequencing (NGS), have drastically reduced the cost and time needed for genomic analysis, enabling the identification of genetic markers associated with diseases. These technologies allow researchers to uncover new drug targets and provide more precise insights into the molecular mechanisms of diseases, thus accelerating the development of genome-based therapies. In September 2023, PacBio announced the collaboration with Hamilton, Integra, Revvity, and Tecan on fully automated preparation protocols for sample preparation for sequencing on the Revio and Sequel 2 systems. This rapid advancement in genomics has become the key driver for transforming drug discovery and development.
- Personalized Medicine: Personalized medicine bases its treatments on an individual's genetic, environmental, and lifestyle information. Using genome-based therapy, it is now possible to identify how a particular genetic makeup determines the response to drugs. More effective treatment options with fewer side effects are realized in genome-based therapies than one-size-fits-all traditional treatment approaches. Therefore, this increased demand for precision medicine, mainly in complex diseases such as cancer, has catapulted genome-based drugs into the market.
- Increasing Prevalence of Genetic Diseases: Awareness and diagnostic capabilities are improving with time, and therefore, the prevalence of genetic diseases, including rare and inherited conditions, is on the rise. Genome-based drugs targeting the root causes of such diseases by identifying specific genetic mutations hold immense promise for treating conditions that were considered untreatable until now. The increasing recognition of these disorders and the growing need for effective treatments are the major drivers of the genome-based drug market.
- Gene Therapy: Gene therapy is a rapidly growing field that involves modifying the genetic material within a patient's cells to treat or cure disease. This includes techniques like gene insertion, gene silencing, and gene editing. With successful treatments already emerging for conditions like spinal muscular atrophy and certain inherited eye diseases, gene therapy represents a major trend in genome-based drug development, offering the potential for permanent cures rather than symptom management.
- CRISPR and Gene Editing Technologies: The ability to make precise changes to the genome has been revolutionized by CRISPR-Cas9 and other gene-editing technologies. By allowing researchers to edit genes at specific locations, CRISPR has the potential to correct genetic mutations that cause diseases, including genetic disorders and cancers. This groundbreaking technology is leading to an explosion of research into genome-based drugs, driving innovation and offering new solutions to previously untreatable conditions.
- Biomarker Discovery: Biomarkers are increasingly playing a crucial role in drug development as specific genetic, molecular, or cellular characteristics may indicate the presence of disease. Biomarker discovery helps identify individuals who will most benefit from a particular treatment, leading to more personalized therapies. This trend is crucial for optimizing the efficacy of genome-based drugs, thereby allowing better patient stratification and an overall improved success rate of clinical trials.
- Rare Disease Treatment: Most rare diseases are due to genetic mutations, and drugs based on genome sequences can address the genetic cause of these diseases directly. Many rare diseases lack effective treatments; therefore, the advent of genome-based therapies, including gene therapies, offers a potential opportunity to provide patients with effective, life-changing treatments. The orphan drug market, targeting rare conditions, is growing fast, and significant opportunities are now available for biotech and pharmaceutical companies.
- Cancer Immunotherapy: Cancer immunotherapy, including drugs like CAR-T cell therapy, exploits the body's immune system in fighting cancer based on genetic mutations of cancerous cells. The results of immunotherapies have been astonishingly promising more so with leukemia and lymphoma, wherein treatment can be specifically tailored for each patient, depending on the genetic makeup. This trend represents enormous opportunities in the development of novel targeted treatments against cancer with enhanced efficacy and reduced side effects.
- Collaborations and Partnerships: Nowadays, genome-based drugs are highly developed in partnership with pharmaceutical firms, biotech companies, and academic institutes. These partnerships would share the required expertise, data, and resources while accelerating the rate of discovery and innovation in genomics. In May 2024, Oxford Nanopore Technologies announced a new Pharmacogenomics Beta Programme in collaboration with Twist Bioscience. The long-read pharmacogenomics solution is available for research use only and is built to provide clear genetic results in one end-to-end workflow from sample to pharmacogenomics star allele call. A collaborative effort of industry players with researchers helps drive the development and brings new genome-based therapies more efficiently to market.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Genome-Based Drug Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Genome-Based Drug Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The major factors driving the Genome-Based Drug Market are Advancements in Genomic Technologies, Personalized Medicine , and Increasing Prevalence of Genetic Diseases
The key future trends of the market are Gene Therapy, CRISPR and Gene Editing Technologies, and Biomarker Discovery
The leading players operating in the Genome-Based Drug Market include Illumina, Inc., Thermo Fisher Scientific, Qiagen, Eurofins Scientific, Agilent Technologies, Oxford Nanopore Technologies, F. Hoffmann-La Roche, Bio-Rad Laboratories, BG
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on the request are an additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Genome-Based Drug Market - By Application
1.3.2 Genome-Based Drug Market - By End-User
1.3.3 Genome-Based Drug Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. GENOME-BASED DRUG MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. GENOME-BASED DRUG MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. GENOME-BASED DRUG MARKET - GLOBAL MARKET ANALYSIS
6.1. GENOME-BASED DRUG - GLOBAL MARKET OVERVIEW
6.2. GENOME-BASED DRUG - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. GENOME-BASED DRUG MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
7.1. OVERVIEW
7.2. APPLICATION MARKET FORECASTS AND ANALYSIS
7.3. ONCOLOGY
7.3.1. Overview
7.3.2. Oncology Market Forecast and Analysis
7.4. CARDIOVASCULAR
7.4.1. Overview
7.4.2. Cardiovascular Market Forecast and Analysis
7.5. METABOLIC
7.5.1. Overview
7.5.2. Metabolic Market Forecast and Analysis
7.6. RARE DISEASES
7.6.1. Overview
7.6.2. Rare Diseases Market Forecast and Analysis
8. GENOME-BASED DRUG MARKET - REVENUE AND FORECASTS TO 2028 - END-USER
8.1. OVERVIEW
8.2. END-USER MARKET FORECASTS AND ANALYSIS
8.3. RESEARCH CENTERS
8.3.1. Overview
8.3.2. Research Centers Market Forecast and Analysis
8.4. ACADEMIC AND GOVERNMENT INSTITUTES
8.4.1. Overview
8.4.2. Academic and Government Institutes Market Forecast and Analysis
8.5. PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
8.5.1. Overview
8.5.2. Pharmaceutical and Biotechnology Companies Market Forecast and Analysis
8.6. OTHERS
8.6.1. Overview
8.6.2. Others Market Forecast and Analysis
9. GENOME-BASED DRUG MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Genome-Based Drug Market Overview
9.1.2 North America Genome-Based Drug Market Forecasts and Analysis
9.1.3 North America Genome-Based Drug Market Forecasts and Analysis - By Application
9.1.4 North America Genome-Based Drug Market Forecasts and Analysis - By End-User
9.1.5 North America Genome-Based Drug Market Forecasts and Analysis - By Countries
9.1.5.1 United States Genome-Based Drug Market
9.1.5.1.1 United States Genome-Based Drug Market by Application
9.1.5.1.2 United States Genome-Based Drug Market by End-User
9.1.5.2 Canada Genome-Based Drug Market
9.1.5.2.1 Canada Genome-Based Drug Market by Application
9.1.5.2.2 Canada Genome-Based Drug Market by End-User
9.1.5.3 Mexico Genome-Based Drug Market
9.1.5.3.1 Mexico Genome-Based Drug Market by Application
9.1.5.3.2 Mexico Genome-Based Drug Market by End-User
9.2. EUROPE
9.2.1 Europe Genome-Based Drug Market Overview
9.2.2 Europe Genome-Based Drug Market Forecasts and Analysis
9.2.3 Europe Genome-Based Drug Market Forecasts and Analysis - By Application
9.2.4 Europe Genome-Based Drug Market Forecasts and Analysis - By End-User
9.2.5 Europe Genome-Based Drug Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Genome-Based Drug Market
9.2.5.1.1 Germany Genome-Based Drug Market by Application
9.2.5.1.2 Germany Genome-Based Drug Market by End-User
9.2.5.2 France Genome-Based Drug Market
9.2.5.2.1 France Genome-Based Drug Market by Application
9.2.5.2.2 France Genome-Based Drug Market by End-User
9.2.5.3 Italy Genome-Based Drug Market
9.2.5.3.1 Italy Genome-Based Drug Market by Application
9.2.5.3.2 Italy Genome-Based Drug Market by End-User
9.2.5.4 Spain Genome-Based Drug Market
9.2.5.4.1 Spain Genome-Based Drug Market by Application
9.2.5.4.2 Spain Genome-Based Drug Market by End-User
9.2.5.5 United Kingdom Genome-Based Drug Market
9.2.5.5.1 United Kingdom Genome-Based Drug Market by Application
9.2.5.5.2 United Kingdom Genome-Based Drug Market by End-User
9.2.5.6 Rest of Europe Genome-Based Drug Market
9.2.5.6.1 Rest of Europe Genome-Based Drug Market by Application
9.2.5.6.2 Rest of Europe Genome-Based Drug Market by End-User
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Genome-Based Drug Market Overview
9.3.2 Asia-Pacific Genome-Based Drug Market Forecasts and Analysis
9.3.3 Asia-Pacific Genome-Based Drug Market Forecasts and Analysis - By Application
9.3.4 Asia-Pacific Genome-Based Drug Market Forecasts and Analysis - By End-User
9.3.5 Asia-Pacific Genome-Based Drug Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Genome-Based Drug Market
9.3.5.1.1 Australia Genome-Based Drug Market by Application
9.3.5.1.2 Australia Genome-Based Drug Market by End-User
9.3.5.2 China Genome-Based Drug Market
9.3.5.2.1 China Genome-Based Drug Market by Application
9.3.5.2.2 China Genome-Based Drug Market by End-User
9.3.5.3 India Genome-Based Drug Market
9.3.5.3.1 India Genome-Based Drug Market by Application
9.3.5.3.2 India Genome-Based Drug Market by End-User
9.3.5.4 Japan Genome-Based Drug Market
9.3.5.4.1 Japan Genome-Based Drug Market by Application
9.3.5.4.2 Japan Genome-Based Drug Market by End-User
9.3.5.5 South Korea Genome-Based Drug Market
9.3.5.5.1 South Korea Genome-Based Drug Market by Application
9.3.5.5.2 South Korea Genome-Based Drug Market by End-User
9.3.5.6 Rest of Asia-Pacific Genome-Based Drug Market
9.3.5.6.1 Rest of Asia-Pacific Genome-Based Drug Market by Application
9.3.5.6.2 Rest of Asia-Pacific Genome-Based Drug Market by End-User
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Genome-Based Drug Market Overview
9.4.2 Middle East and Africa Genome-Based Drug Market Forecasts and Analysis
9.4.3 Middle East and Africa Genome-Based Drug Market Forecasts and Analysis - By Application
9.4.4 Middle East and Africa Genome-Based Drug Market Forecasts and Analysis - By End-User
9.4.5 Middle East and Africa Genome-Based Drug Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Genome-Based Drug Market
9.4.5.1.1 South Africa Genome-Based Drug Market by Application
9.4.5.1.2 South Africa Genome-Based Drug Market by End-User
9.4.5.2 Saudi Arabia Genome-Based Drug Market
9.4.5.2.1 Saudi Arabia Genome-Based Drug Market by Application
9.4.5.2.2 Saudi Arabia Genome-Based Drug Market by End-User
9.4.5.3 U.A.E Genome-Based Drug Market
9.4.5.3.1 U.A.E Genome-Based Drug Market by Application
9.4.5.3.2 U.A.E Genome-Based Drug Market by End-User
9.4.5.4 Rest of Middle East and Africa Genome-Based Drug Market
9.4.5.4.1 Rest of Middle East and Africa Genome-Based Drug Market by Application
9.4.5.4.2 Rest of Middle East and Africa Genome-Based Drug Market by End-User
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Genome-Based Drug Market Overview
9.5.2 South and Central America Genome-Based Drug Market Forecasts and Analysis
9.5.3 South and Central America Genome-Based Drug Market Forecasts and Analysis - By Application
9.5.4 South and Central America Genome-Based Drug Market Forecasts and Analysis - By End-User
9.5.5 South and Central America Genome-Based Drug Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Genome-Based Drug Market
9.5.5.1.1 Brazil Genome-Based Drug Market by Application
9.5.5.1.2 Brazil Genome-Based Drug Market by End-User
9.5.5.2 Argentina Genome-Based Drug Market
9.5.5.2.1 Argentina Genome-Based Drug Market by Application
9.5.5.2.2 Argentina Genome-Based Drug Market by End-User
9.5.5.3 Rest of South and Central America Genome-Based Drug Market
9.5.5.3.1 Rest of South and Central America Genome-Based Drug Market by Application
9.5.5.3.2 Rest of South and Central America Genome-Based Drug Market by End-User
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL GENOME-BASED DRUG MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Rest of the World
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. GENOME-BASED DRUG MARKET, KEY COMPANY PROFILES
12.1. ILLUMINA, INC.
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. THERMO FISHER SCIENTIFIC
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. QIAGEN
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. EUROFINS SCIENTIFIC
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. AGILENT TECHNOLOGIES
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. OXFORD NANOPORE TECHNOLOGIES
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. F. HOFFMANN-LA ROCHE
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. BIO-RAD LABORATORIES
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. BGI
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. DANAHER CORPORATION
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
12.11.
12.11.1. Key Facts
12.11.2. Business Description
12.11.3. Products and Services
12.11.4. Financial Overview
12.11.5. SWOT Analysis
12.11.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1. Illumina, Inc.
2. Thermo Fisher Scientific
3. Qiagen
4. Eurofins Scientific
5. Agilent Technologies
6. Oxford Nanopore Technologies
7. F. Hoffmann-La Roche
8. Bio-Rad Laboratories
9. BGI
10. Danaher Corporation
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For